



Journal Homepage: -www.journalijar.com
**INTERNATIONAL JOURNAL OF
 ADVANCED RESEARCH (IJAR)**

Article DOI:10.21474/IJAR01/18096
 DOI URL: <http://dx.doi.org/10.21474/IJAR01/18096>



RESEARCH ARTICLE

ROLE OF THE SKIN MICROBIOME IN DERMATOLOGY : A LITERATUREREVIEW

Belcadi Jihane MD, Oulad Ali Sara MD, Senouci Karima MD and Benzekri Laila MD

From the Department of Dermatology, Mohammed V University in Rabat, Ibn Sina University Hospital, Morocco.

Manuscript Info

Manuscript History

Received: 05 November 2023

Final Accepted: 09 December 2023

Published: January 2024

Key words:-

Skin, Microbiome, Dysbiosis, Probiotics

Abstract

The skin is a complex barrier organ made of a symbiotic relationship between microbial communities and host tissue via complex signals provided by the innate and the adaptive immune systems. It is constantly exposed to various endogenous and exogenous factors which impact this balanced system potentially leading to inflammatory skin conditions comprising infections, allergies or autoimmune diseases. Recently, interest has extended beyond the gastrointestinal microbiome to include the skin microbiome and its impact on various skin diseases. This article aims to provide an overview on the knowledge about the skin microbiota, the microbiome and their importance in dermatology.

Copy Right, IJAR, 2024,. All rights reserved.

Introduction:-

The skin, a primordial organ of the human being, constitutes a favourable environment for the development of micro-organisms. These microorganisms are mostly harmless, and in some ways indispensable to humans.

The first microscopic observations of microorganisms colonising the skin date back to 1683 by Van Leeuwenhoek. But the real research on microflora by culture methods was introduced by Kligman in the 1950s.

In the year 2000, Nobel laureate Lederberg suggested the term 'human microbiome' to refer to the collective genome of our microflora.¹

The microbiota is present in the various parts of the body in which an epithelium is in contact with the outside world: the digestive tract (stomach and intestines), the skin, the respiratory tract (mouth, pharynx and lungs) and the urogenital system.

It thus forms a complex ecosystem whose composition is the result of a balance between local conditions and the metabolic properties of these microorganisms.

Recently, interest has extended beyond the gastrointestinal microbiome to include the skin microbiome and its impact on various skin diseases.

As skin dysbiosis is frequently observed in dermatological pathologies, the crosstalk between the gut and the skin could offer targeted pathways with obvious therapeutic potential in dermatological practice; probiotics.

Corresponding Author:- Belcadi Jihane MD

Address:- From the Department of Dermatology, Mohammed V University in Rabat, Ibn Sina University Hospital, Morocco.

Objectives:-

We present here the current data on the role of the microbiome in dermatology and the interest of probiotics in modulating it.

Our objective is to evaluate whether the data in the literature support the usefulness of oral and topical probiotics for certain dermatological diseases where the microbiota interfere in their pathogenesis.

Method:-

A literature review was conducted in PubMed and Google Scholar databases to find relevant studies with the keywords "microbiome", "microbiota", "dysbiosis", "dermatology", "probiotic", "skin" and "dermatological conditions".

All search terms were used in various combinations and studies were selected for relevance based on their abstracts.

Basic science, in vitro research, animal model studies and clinical trials were included.

Studies written in languages other than English and French were not included.

The cutaneous microbiome and microbiota

The microbiota comprises all living members forming the microbiome²².

The microbiome is defined as the collective genome of microorganisms. Therefore, the skin microbiome is the genome of the microorganisms present on the skin.

The skin microbiota comprises two groups:

- Resident microorganisms, which are a relatively fixed group (the core microbiota) and recover quickly after a disturbance. This is the basic microbiota considered as commensal.
- Transient microorganisms that originate from the environment and take advantage of a change in habitat to proliferate.

Although microbiota research has so far largely focused on the identification of bacteria, other types of skin colonisers should not be forgotten; yeasts such as *Malassezia* and arthropods such as *Demodex*. Viruses remain to date the least known members of the skin microbiota²².

Temporal and spatial variability of the microbiota

In the skin, the microbiome is variable from one area to another depending on physiological characteristics such as humidity, seborrhoea and the degree of exposure to the external environment²⁴.

The skin microbiome also varies during life from birth to senescence. The skin of the foetus will be colonised by micro-organisms from the mother from birth²³. This initial flora is not very diversified and resembles that of the place of delivery, i.e. a vaginal delivery will lead to colonisation by the vaginal flora, whereas after a caesarean section, colonisation will be done by the flora typical of the skin of the belly²³. This process of colonisation of the skin at the beginning of life is necessary to establish an immune tolerance to commensal microorganisms²³.

Variation by site

Three microenvironments have been defined:

- Sebaceous regions (forehead, retroauricular folds, nostrils and back) are dominated by *Propionibacterium* spp. as the main residents of the pilosebaceous unit.
- The moist regions (armpits, elbow creases, umbilicus, inguinal creases and intergluteal creases) are the ecological niches of *Staphylococcus* and *Corynebacterium* spp. Indeed, the breakdown of apocrine sweat by *Corynebacteria* and *Staphylococcus* is responsible for the odour associated with sweating in humans²⁵.
- The dry areas (forearms, hands and buttocks) are the site of the greatest microbial diversity with a particular abundance of Gram-negative germs that were thought to colonise the skin only rarely and were considered contaminants of the gastrointestinal tract. In these dry areas, the phylogenetic diversity is greater than in the intestine

and oral mucosa of the same individual. The four phyla (Acinetobacter, Firmicutes, Bacteroidetes and Proteobacteria) are represented in varying proportions².

Variations in the mycobiome are also observed depending on the site:

- The central part of the body and the arms are dominated by Malassezia.
- The feet, which are the main site of mycotic infections, are characterised by the diversity of the microbiota and are colonised by Malassezia, Aspergillus, Cryptococcus, Rhodotorula and Epicoccum²⁶.

Gender variation

Gender also has an impact on the microbiota. From birth, a difference in the lipid composition of the vernix caseosa between male and female newborns appears to influence microbial colonisation. Anatomical and physiological characteristics of the skin (thickness, pH, composition, sebum level and use of cosmetics) could explain the difference between the two genders at the same anatomical site²⁷.

The skin pH is generally more acidic and sebum secretion higher in males compared to females of the same age.

The study of the microbiota of the hand shows that women have a higher microbiological diversity compared to men²⁸.

The genitalia of the two sexes also have a different specific microbiome (Lactobacillus and Gardnerella in women, Corynebacterium in men).

Inter-individual variability

Inter-individual variability can sometimes be marked. Indeed, the palm microbiota is so specific to each individual host that it has been proposed to use it as a forensic identification tool. Several extrinsic factors (lifestyle, personal hygiene, location, sun exposure, cosmetics and local or systemic antibiotic therapy) are thought to be responsible for inter-individual variations in the microbiome.²

Role of the microbiome

In order to prevent colonisation and invasion by pathogens, commensal germs firstly engage in competitive mechanisms both geographically (competition to occupy the same sites of adhesion) and nutritively (consumption of the same substrates)³⁰.

P. acnes resident in the sebaceous gland, thanks to its lipolytic enzymes, produces free fatty acids which, together with the sebum, decrease the skin pH and inhibit the proliferation of several germs³⁰. Competitive exclusion also involves the production of bacteriocins and antimicrobial factors. For example, some strains of *Staphylococcus epidermidis* secrete serine protease Esp which inhibits biofilm formation and thus colonisation by *S. aureus*³¹. On the other hand, *S. epidermidis* controls the growth and proliferation of *P. acnes* through glycerol fermentation and succinic acid production^{32, 33}.

Stimulation and regulation of the skin's immune system

The skin is home to a large number of effector cells of innate and adaptive immunity.

The primary skin defence system of innate immunity relies on an arsenal of antimicrobial peptides (AMPs) and enzymes (lysozyme, ARNase and the S100 family of proteins) produced by keratinocytes. The main role of skin peptides and proteins is to inactivate microorganisms by disrupting their membrane integrity or by enzymatic degradation of the cell wall. Cells of the cutaneous adaptive immunity system include antigen-presenting cells including Langerhans cells and lymphocytes²⁹.

The skin microbiota stimulates innate immunity and the regulation of pathogen colonisation but must in turn escape it to ensure this continued stimulation²⁹.

The process of skin colonisation in the neonatal period is crucial in establishing this immune tolerance to commensal germs.

The skin microbiota induces an appropriate level of IL 17 and IFN gamma producing T cells and FOXP3 expressing regulatory T cells.

Early exposure of neonates to *S. epidermidis* induces specific FOXP3+ regulatory T cells that contribute to the inhibition of the excessive pro-inflammatory response to commensal bacteria²⁹.

This exposure also stimulates defence mechanisms against *S. aureus* by increasing the expression of genes for certain antimicrobial peptides, in particular beta-defensins 2 and 3²⁹.

Skin dysbiosis

Dysbiosis is by definition an imbalance of the microbiota, the equilibrium state being called eubiosis.

This imbalance is generally linked to a loss of microbiota diversity in favour of an abundance of pathogenic germs. It can therefore occur at different levels, ranging from the taxonomic composition to the functions of these microorganisms.

The list of dermatoses with which a dysbiosis may be associated is constantly growing.

However, it is difficult to confirm whether dysbiosis is a cause or a consequence in these diseases.

Dermatological conditions related to the microbiome

1) Inflammatory conditions:

- Atopic dermatitis

Atopic dermatitis is a chronic inflammatory dermatosis that affects 15-20% of children and 2-10% of adults. Atopic dermatitis results from a complex interaction between genetic susceptibility, skin barrier dysfunction, innate and adaptive immunity and the microbiome.

The study of the microbiota during atopic dermatitis shows that the dysbiosis associated with flare-ups is characterised by a decrease in microbial diversity, with massive colonisation by *S. aureus*, which can represent up to 90% of the microbiota.

S. epidermidis, a commensal present on healthy skin, appears to be the best antagonist of *S. aureus*. *S. epidermidis* is thought to maintain the balance of the skin microbiome by integrating innate immune pathways that control effector T-cell function and by exerting an antimicrobial function through the production of IL-1a by dendritic cells and keratinocytes, thereby limiting the ability of pathogens to establish infections. Clinically, Byrd et al. showed that the least severe atopic dermatitis flare-ups had higher numbers of *S. epidermidis* while the most severe flare-ups were associated with *S. aureus*³.

S. aureus exploits the skin barrier defects associated with atopic dermatitis with a decrease in antimicrobial peptides and the low acidic environment to ensure its colonisation. *S. aureus*-derived toxins and proteases further damage the skin barrier and induce adaptive and innate immune responses³.

Malassezia spp. colonisation increases with the severity of atopic dermatitis and has been detected in up to 90% of skin lesions. Its pathophysiological role may be due to the activation of pro-inflammatory cytokines and autoreactive cells that increase the expression of TLR2 and TLR4 through the secretion of immunogenic proteins³.

Antimicrobial agents eradicate *S. aureus*, however, they also affect other members of the skin microbiome, disrupting homeostasis between species and generating bacterial resistance.³

In addition to dysbiosis, the skin of those with atopic dermatitis is deficient in sphingolipids and potential downstream antimicrobial peptides, even in the absence of clinical symptoms. The sphingolipid pathway, which includes sphingomyelins, ceramides, phospholipids, and arachidonic acid, has been directly linked to atopic dermatitis through its importance in the control of *Staphylococcus aureus*, epithelial barrier function, and immune regulation²¹.

Based on these reports, Ian A. Myles' team hypothesised that defects in lipid production by Gram-negative bacteria might contribute to atopic dermatitis. After modifying previous protocols for culturing sphingolipid-producing bacteria, they presented a method for systematically collecting cultivable Gram-negative bacteria. The most frequently cultured species in healthy volunteers was *Roseomonas mucosa*²¹. They proposed a topical treatment with *R. mucosa* which was associated with an improvement in disease severity, an improvement in epithelial barrier function, a reduction in the load of *Staphylococcus aureus* on the skin and a reduction in the need for topical steroids without serious adverse effects²¹.

- Seborrhoeic Dermatitis

Seborrhoeic dermatitis, another common chronic inflammatory dermatosis, is characterised by recurrent oily scales, sometimes accompanied by erythema and itching. Although the exact pathophysiology of the disease is still unclear, current theories point to the role of the microbiota present on the skin surface in the pathogenesis of seborrhoeic dermatitis.

A dysbiosis in the composition of the bacterial microbiome has been demonstrated in seborrhoeic dermatitis lesions. An increased level of *Staphylococcus* has been found in lesion sites, and its relative abundance is positively correlated with damage to the epidermal barrier during seborrhoeic dermatitis⁴.

- Acne

Acne is a chronic inflammatory disorder of the pilosebaceous follicle that affects over 85% of adolescents and young adults. Its pathogenesis includes increased sebum production, follicular hyperkeratinisation, inflammation, involvement of the skin microbiome, and *Cutibacterium acnes*.

Acne has been widely associated with the proliferation of *C. acnes*. However, several authors have found that the abundance and bacterial load of *C. acnes* do not differ significantly between acne patients and healthy patients. It seems that the severity of acne is associated with a loss of *C. acnes* strain diversity compared to healthy individuals. Thus, acne would be triggered by the selection of a subset of *C. acnes* strains, including the IA1 phylotype, which is predominant in facial acne and probably enhanced by a hyperseborrhoeic environment.¹⁷

C. acnes triggers the release of pro-inflammatory cytokines after binding to TLR-2 that activate NLRP3 inflammasomes and caspase-1, leading to IL-1 β secretion, T-cell differentiation and recruitment of lymphocytes and neutrophils into acne lesions.

TLR-2 activation also stimulates the production of IL-1 α , which plays a central role in comedogenesis through the stimulation of keratinocyte proliferation. *C. acnes* can also form biofilms that increase virulence and resistance to antimicrobial treatments³.

S. epidermidis inhibits the proliferation of *C. acnes* by promoting glycerol fermentation and releasing succinic acid. It also reduces *C. acnes*-induced skin inflammation by producing lipoteichoic acid, which inhibits the production of TLR2, IL-6 and TNF α by keratinocytes. On the other hand, *C. acnes* inhibits the proliferation of *S. epidermidis* by maintaining the acidic environment of the pilosebaceous follicle, hydrolysing sebum triglycerides and secreting propionic acid. The loss of balance between them leads to the activation of markers related to inflammation³.

Malassezia may also play a role in refractory acne. Its lipase, which is 100 times more active than that of *C. acnes*, attracts neutrophils and stimulates the release of pro-inflammatory cytokines from monocytes and keratinocytes. However, its exact involvement in the pathogenesis of acne remains to be determined³.

Tetracyclines are the first choice of treatment for moderate/severe acne because they suppress the growth of *C. acnes* and control inflammation. However, the antimicrobial activity also alters the skin microbiota, which may be beneficial.

Recently, Yang et al. demonstrated in 5 patients with moderate to severe acne that photodynamic therapy increased the diversity of the skin microbiome in acne and shifted the follicular microbiome to the epidermal microbiome, exerting its beneficial effect in part by inhibiting *C. acnes* and altering the composition and potential function of the skin microbiome in acne.³

- Rosacea

Rosacea is a complex facial skin condition combining abnormal inflammation and vascular dysfunction. In addition to known triggers, the role of the microbiota in the development and aggravation of rosacea continues to be of interest. *Demodex folliculorum*, *Helicobacter pylori*, *Staphylococcus epidermidis*, *Chlamydia pneumoniae* and the *Demodex*-associated bacterium *Bacillus Oleronius* are microorganisms that have been associated with rosacea⁵.

Pattern recognition receptors (PRRs) expressed on the skin participate in a continuous immune surveillance that allows symbiotic micro-organisms to thrive while eliminating potential pathogens. Two of these PRRs, TLR-2 and the NOD (nucleotide binding oligomerization domain) family receptor, are upregulated in rosacea patients, and their activation by *Demodex* is thought to trigger inflammation during rosacea⁵. Indeed, chitin (from the mite exoskeleton) can stimulate the pro-inflammatory response of keratinocytes via TLR-2, and mite allergens have been shown to activate NOD-like receptors *in vitro*.

The microbiota residing on *Demodex* mites may also be involved in this process: *B. Oleronius* antigens are reported to induce mononuclear blood cell proliferation in rosacea patients, and to stimulate the production of cathelicidin, MMP-9, tumour necrosis factor (TNF) and interleukin (IL)-8 by neutrophils from healthy subjects⁵. In rosacea patients, this inflammatory state leads to an increase in facial skin temperature. This in turn may affect the growth and balance of the microbiota, and alter the behaviour of *S. epidermidis* so that it secretes more proteins. In addition, because *S. epidermidis* antigens are recognised by TLR-2, the bacteria also participate in skin inflammation.⁵

Psoriasis

Psoriasis is a common dermatosis with a worldwide prevalence of 2%. It results from a complex interaction between genetic predisposition and environmental factors that induce immune dysregulation and trigger rapid proliferation of keratinocytes and infiltration of immune cells with the formation of erythematous and scaly plaques.

The breakdown of immune tolerance to skin microorganisms has been implicated in the pathogenesis of psoriasis. Bacteria found on psoriasis plaques include Firmicutes, Actinobacteria and Proteobacteria.

Several studies have shown an increase in the number of *Staphylococcus* in the skin of a psoriatic subject compared with the skin of healthy individuals.

S. aureus colonises psoriatic lesions in 35% of patients²⁰ and up to 60% secrete enterotoxins and toxic shock syndrome toxin-1. Colonisation by *S. aureus* is thought to trigger a Th17 inflammatory response responsible for the perpetuation and proliferation of keratinocytes.

S. pyogenes is also frequently identified as a trigger for both the development and exacerbation of psoriasis. Pharyngeal infection with *S. pyogenes* induces activation of superantigens and thus of T4 cells.

The association of *Malassezia* with psoriasis is unclear. Its presumed involvement is based on the ability of *Malassezia* to invade keratinocytes, which in turn increase the expression of TGF β , integrin chains and heat shock protein 70, which induce keratinocyte hyperproliferation. In addition, through the secretion of chemotactic factors, *Malassezia* attracts neutrophils to psoriasis lesions⁴.

Candida albicans has been linked to the persistence and worsening of skin lesions, particularly in reverse psoriasis. The mechanism remains unknown, however, it may be mediated by superantigens⁴.

With regard to viruses, patients infected with human immunodeficiency virus or human papillomavirus show more severe features of psoriasis related to the secretion of substance P, which stimulates keratinocyte proliferation.⁴

- Maskne

"Maskne" is a new term that emerged during the COVID-19 pandemic. It refers to a subset of mechanical acne, which merits consideration for widespread use of reusable cloth masks to control the pandemic worldwide.

The pathophysiology of this entity is directly related to the new skin microenvironment and textile-skin friction created by mask wearing.

The occlusive microenvironment leads to a dysbiosis of the microbiome, which is linked to various dermatological conditions such as acne, but also perioral dermatitis, rosacea and eczema by creating a new wet intertriginous zone favouring the proliferation of certain microbial communities such as Staphylococcus and Corynebacteria.¹⁰

2) Autoimmune diseases:

- Bullous pemphigoid

The study of the microbiota in patients with bullous pemphigoid shows a significant difference in the microbiological profile at the peri-lesional sites compared to the same location in healthy controls. In these sites there is a decrease in acinobacteria and proteobacteria, and a significant increase in firmicutes.¹²

It is unclear how dysbiosis may contribute to the pathogenesis of bullous pemphigoid. In this regard, it is interesting to note that complement gene expression in keratinocytes is not regulated by bacteria. In addition, *S. aureus* is a known inducer of proteases and elastases, expressed in human keratinocytes and eosinophilia, which process basement membrane structural proteins and mediate pruritus. Interestingly, *S. aureus* can also produce these enzymes by itself. Despite these considerations, we cannot exclude that dysbiosis in bullous pemphigoid is the consequence and not the cause of the disease. There is growing evidence to support a role for commensal bacteria in modulating the immune system, including the production of antimicrobial peptides (AMPs), activation of Toll-like receptors (TLRs) and induction of complement gene expression. On the other hand, the breakdown of the epidermal barrier makes the skin particularly susceptible to colonisation by many bacteria.¹²

- Systemic lupus erythematosus

The correlation between systemic lupus erythematosus and microbiota colonisation has received much attention in recent years. Variations in the abundance of the genus *Staphylococcus* have been identified, in particular *Staphylococcus aureus* and *Staphylococcus epidermidis*, colonising skin lesions in systemic lupus erythematosus patients, which may effectively distinguish systemic lupus erythematosus skin lesions from healthy skin.¹¹

Several studies have shown the association of variations in the skin microbiome with specific lupus involvement; renal tropism, complement consumption, etc.

The presence of nasal colonisation by *Staphylococcus aureus* is associated with renal manifestations and autoantibody positivity in systemic lupus erythematosus, indicating that regional change in the skin microbial community may affect not only the local immune microenvironment but also the whole system of systemic lupus erythematosus patients.¹¹

- Vitiligo

All studies agree that there is no significant difference in the richness and uniformity of the microbiota in vitiligo lesions, but rather differences in community composition.

Either a significant increase in *Streptomyces* and *Streptococcus* in vitiligo lesions¹⁹ or depletion of *Staphylococcus* and *Acinetobacter* versus enrichment of pathogenic *Paracoccus* (Proteobacteria) in lesional skin¹⁸.

Streptomyces can produce a variety of metabolites such as decomposition enzymes and anti-biomass for various substances¹⁹. Tacrolimus is derived from streptomycin and is currently a calcineurin inhibitor, which plays an important role in the treatment of vitiligo either as monotherapy or in combination with phototherapy¹⁹. Recently, the efficacy of topical application of tacrolimus 0.1% twice weekly in the prevention of vitiligo recurrence has been reported¹⁹. Assuming that *Streptomyces* can produce certain immunosuppressants, similar to tacrolimus, which slow down the disease process, their increased population in active vitiligo lesions could be a mechanism of skin self-regulation or be involved in the pathogenesis of vitiligo¹⁹.

The study by Bziouche H. et al highlighted the interaction between mitochondria and microbiota. It has been shown that mitochondrial genotype modulates both reactive oxygen species (ROS) and microbiota during vitiligo¹⁸.

Thus this study reported significant mitochondrial damage in the lesional skin of patients¹⁸.

The change in the microbiome only in biopsy samples with mitochondrial DNA strongly supports a mitochondrial stress-induced change in the microbiome. Interestingly, the genus that was almost completely absent in patients with mitochondrial DNA in the skin is *Bifidobacterium*, which is well known to have protective effects and to decrease activation of innate immune cells¹⁸.

Bziouche H. et al were able to demonstrate that primitive mitochondrial stress in some patients with vitiligo could be responsible for changes in the skin microbiome. This skin dysbiosis could then trigger the innate response via PAMPs and lead to the production of IFNs and chemokines¹⁸.

3) Infectious diseases:

- Leishmaniasis

The study of the role of the microbiota in cutaneous leishmaniasis has shown that infection by leishmania-type parasites leads to a decrease in the bacterial diversity of the skin, characterised by communities dominated by *Staphylococcus* spp. and/or *Streptococcus* spp.¹³ This suggests that disease-associated changes in the skin microbiota ("dysbiosis") contribute to the genesis of lesions and dermal cellular responses, including immune and inflammatory responses to *L. major* infection. The dysbiosis induced by leishmaniasis is not limited to the site of infection, but occurs globally on the skin with the possibility of being transferred to uninfected subjects living in cohabitation.

- Opportunistic infections

Although commensal microorganisms generally live peacefully in our bodies, many have the ability to cause infections in the right context. *S. epidermidis*, despite its many beneficial roles as described above, is a common cause of infections, including nosocomial deep tissue infections involving indwelling medical devices such as catheters.³ In addition, many bacteria present in the normal skin microbiome frequently cause infections in chronic wounds with delayed healing, which frequently occur in diabetic patients and the elderly.³ While many factors in host biology contribute to the impaired healing of these wounds, it should be noted that the immune response to these commensal germs in previously sterile tissue, which leads to prolonged inflammation, exacerbates the problem and creates a vicious circle.³

4) Neoplasia:

- Non-melanocytic

Since the global incidence of skin cancers is increasing exponentially, a question frequently arises; how an individual's microbiota, which is ten times more numerous than human cells, can influence skin cancer risk and subsequent response to therapy.

As microbial dysbiosis is linked to chronic inflammation, inflammation-mediated carcinogenesis processes and immune evasion, it is not surprising that the microbiota is associated with the development of specific cancers⁷.

Such a mechanism is possible in the case of cutaneous squamous cell carcinomas because

S. aureus infection triggers inflammation-related signalling and the release of cytokines such as tumour necrosis factor-alpha, which has already been identified as being involved in squamous cell carcinogenesis. Thus, numerous studies have found a strong association of

S. aureus DNA with skin squamous cell carcinoma. This association is stronger than what has been found for squamous cell carcinoma and HPV⁷.

The increased prevalence of *S. aureus* DNA also in actinic keratosis biopsies (compared to seborrhoeic keratosis) is interesting because actinic keratosis is considered a precursor to the development of squamous cell carcinoma, which might suggest that increased *S. aureus* colonisation is observed already at the beginning of the carcinogenic process⁷.

S. aureus is not normally able to infect an immunocompetent person unless the normal barriers have been broken, for example by surgery or burns, which are known to promote squamous cell carcinoma⁷.

- Melanocytic

For melanoma, current studies only concern the pig skin microbiome because of its high similarity to that of human skin⁷. Thus, significant differences were found in bacterial compositions and microbial diversity between melanoma and normal skin samples⁷. The abundance of *Fusobacterium* and *Trueperella* was higher in melanoma skin samples than in controls⁷. In addition, increased abundance of *Fusobacterium nucleatum* was associated with disease progression. Among *Fusobacterium*, *Fusobacterium nucleatum* can potentiate tumour proliferation by inhibiting NK cell cytotoxicity through the interaction of *Fusobacterium* Fap2 protein and T cell immunoglobulin and ITIM domain⁷.

5) Capillary pathologies:**- Folliculitis decalvans**

Folliculitis decalvans is a primary scarring alopecia whose pathophysiology is unclear. Arguments for a link between bacterial communities and disease development are based on the fact that *S. aureus* is often cultured from lesion swabs, and that in most cases the response to antimicrobial therapy is temporarily good⁹. In addition, biofilm-like structures consisting of *C. acnes* have been identified in hair follicles from biopsy samples (species confirmed by in situ hybridisation) and in plucked hair follicles (bacterial species suspected on the basis of their morphology) from some folliculitis decalvans patients⁹. Although such structures have also been found in plucked hair follicles of healthy individuals, the biofilm hypothesis is quite convincing⁹. The persistence of the disease despite transiently effective antibiotic therapy, the infiltration of neutrophils on histology, which destroy the follicle but are not able to destroy the biofilm, and the normal immune background of the patients, are listed among the supporting arguments. The current hypothesis is that an initially non-pathogenic biofilm can spread and develop into a pathogenic form causing inflammation⁹. Antibiotic treatment can kill the planktonic form of the bacteria released by the biofilms and even temporarily remove the symptoms, but the remaining biofilm cells are the nest of the chronic infection⁹.

- Androgenetic alopecia

Androgenetic alopecia is characterised by a shortening of the anagen phase and a miniaturisation of the hair follicle that progresses slowly over time. Infiltration of mononuclear cells and lymphocytes is detected in about 50% of skin samples⁹. This microinflammation occurs in the upper third of the hair follicle, where a large number of microorganisms are harboured⁹. In addition, complement-stimulating porphyrins produced by *Cutibacterium* spp. were identified in the pilosebaceous canal of 58% of the androgenetic alopecia patients compared to 12% of the control group⁹. These arguments, together with the improvement observed after the application of antimicrobial agents, may suggest a possible link with the skin microbiota⁹.

- Alopecia areata

Alopecia areata is a non-scarring alopecia with an incidence of 2% and a higher prevalence in paediatric populations.

The pathogenesis of alopecia areata remains incompletely understood. Autoimmune-mediated hair follicle destruction, upregulation of inflammatory pathways and loss of immune privilege in the hair follicle are thought to be involved in the development of this condition. Genetic predisposition, environmental factors and, recently, the skin microbiome have been linked to autoimmunity in alopecia areata³.

The microbiota of the hair follicle is located near the bulge (stem cell niche) and the bulb (site of cell division), which are considered immune privileged sites³.

Changes in the hair follicle microbiome may be related to the loss of homeostasis, modulation of immune responses and intense peribulbar inflammation in hair loss³.

The symbiosis of *Corynebacteriaceae*, *Propionibacteriaceae*, *Staphylococcaceae* and *Malassezia* is linked to a healthy scalp, whereas dysbiosis can cause pathological conditions. Pinto et al. found microbial changes in people with alopecia, with over-colonisation by

C. acnes and reduced abundance of *S. epidermidis*, but it has not been determined whether these differences are the cause or consequence of the disease. The role of CMV in the initiation of alopecia was suggested after finding DNA sequences in skin biopsies from alopecic areas³. Rudnicka et al. hypothesised a possible relationship between colonisation of the scalp by *Alternaria* spp. and alopecia after its culture from skin scrapings in patients³.

6) Genodermatoses - Netherton syndrome

Netherton syndrome is a severe ichthyosis characterised by desquamative skin inflammation, elevated IgE levels, extensive allergic sensitisation, neonatal growth retardation and recurrent bacterial skin infections⁶. It is an autosomal recessive disease characterised by mutations in the serine protease inhibitor type 5 (SPINK5) gene resulting in uninhibited protease activity and thus a barrier defect and constant inflammation of the skin with increased levels of pro-inflammatory cytokines and the type 17 T helper pathway⁶.

The skin inflammation of Netherton syndrome resembles that of atopic dermatitis and hyper-IgE syndrome. Microbiota diversity is reduced and *S. aureus* is frequently isolated from skin lesions and during disease flares⁶.

An association of skin microbiota diversity with specific subclasses of lymphocytes and NK cells has been demonstrated, the same cells that are altered in patients with Netherton syndrome and correlate with the frequency of skin infections and increased antibiotic use⁶.

What about probiotics?

Modification of the microbiota through the use of faeces has been described for over 500 years, but the use of specific strains of bacteria to achieve a specific clinical impact has only been of interest for the last 50 years. In fact, the first definition of probiotics was described in 1965 by Lilly and Stillwell and was limited to substances produced by bacteria that promote the growth of other bacteria. In 1989, the notion of a living microbial supplement appeared, although this definition was still linked only to nutritional health. The latest, current definition considers probiotics as living micro-organisms that must be ingested in sufficient quantities to have a positive effect on health that is not limited to nutritional effects. These three definitions allow us to understand how probiotics can have an impact on health: by acting on the resident microbiota, the cells of the intestinal epithelium and, globally, on the immune system.

The microbiota acts in a web-like interaction to suppress virulence-related genes and promote genes associated with commensalism; by producing bioactive molecules, the microbiota influences the development of appendages, tumorigenesis, ageing, sensory nerve function and the innate immune system.

Probiotics are known to block the release of inflammatory cytokines and signalling pathways and thus help reduce skin inflammation and restore skin barrier function. As we have seen, the state of the barrier is fundamental to skin defence and immune guidance. Restoration of the barrier is associated with improved clinical outcomes.

Oral probiotics may improve skin health through a gut-brain-skin axis that reduces systemic and brain inflammation. The GBS axis improves nutrient absorption, which promotes barrier synthesis. Oral ingestion of *Lactobacillus reuteri* reduces perifollicular inflammation. Other probiotics targeting skin disorders have improved atopic dermatitis, healing of burns and scars in general, and even skin aging.

As shown by the example of psoriasis, where oral administration of *Lactobacillus pentosus* significantly reduces erythema, desquamation and thickening of the epidermis.

The reduction in the expression of inflammatory cytokines, namely TNF- α , IL-6 and pro-inflammatory cytokines in the IL-23/IL-17 cytokine axis, upon administration of probiotics suggests a possible therapeutic modality to manage psoriasis.

Topical application of the probiotics *L. bulgaricus*, *L. acidophilus* or *L. plantarum* improves the outcome of acne by reducing *Cutibacterium acnes* colonisation of the skin.

Soluble pro-inflammatory molecules, such as substance P, associated with the spread of skin inflammation are reduced after topical application of *L. paracasei*, and keratinocyte expression of the NF- κ B pathway is inhibited after topical application of

Streptococcus salivarius K12. Similarly, production of the anti-inflammatory molecule IL-10 by dendritic cells is increased after topical application of *Vitreoscilla filiformis* extracts on atopic dermatitis. As well as topical application of *R. mucosa*, which is associated with a significant improvement in atopic dermatitis lesions²¹.

Topical probiotics have also entered the world of skin care with their use in photoaging and skin aging. Although clinical trials are underway, one study has shown that probiotics slow down the photoaging process, reduce oxidative stress and improve the skin's barrier function. Researchers found a significant improvement in the severity of wrinkle depth, hyperpigmentation of the forehead and glabella in the group receiving a high topical concentration of probiotic¹⁴.

Conclusion:-

Molecular approaches to defining microbial diversity have changed our understanding of the skin microbiome and raised several questions regarding host-microbe interaction and its relevance to skin diseases. Current knowledge has shown that bacterial, fungal and viral species are under- or over-expressed in several dermatoses compared to healthy skin.

To date, the pathogenic role of several species has been suggested in various skin diseases, such as *C. acnes* in acne or *S. aureus* in atopic dermatitis. However, the paradigm of the microbiome related to certain skin diseases has shifted from the proliferation of one or more microorganisms to the loss of diversity among several microorganisms in the production of disease.

Finally, as antimicrobial treatments directed against pathogens associated with skin diseases also eradicate the beneficial flora, research efforts have been directed towards maintaining the homeostasis of the skin microbiota through the use of probiotics, prebiotics, symbiotics and faecal transplants. In the near future, their real therapeutic effectiveness will certainly be established.

Declarations

- Ethics approval and Consent to participate : not applicable
- Consent for publication : not applicable
- Availability of data and materials : no data
- Competing interests : no competing interests
- Funding : non funding
- Authors' contributions : all authors contributed to the writing of this article

Acknowledgements:-

To all authors and to the dermatology department of the IBN SINA university hospital in Rabat.

References:-

1. Microbiome in healthy skin, update for dermatologists. B. Dréno, E. Araviiskaia, Berardesca, G. Gontijo, M. Sanchez Viera, L.F. Xiang, R. Martin, T. Bieber.
2. Microbiome cutané. A. Souissi, M. Mokni.
3. The Human Skin Microbiome in Selected Cutaneous Diseases
Silvia Carmona-Cruz, Luz Orozco-Covarrubias and MarimarSaez-de-Ocariz.
4. Skin microbiome alterations in seborrheic dermatitis and dandruff: A systematic review Rong Tao, Ruoyu Li, Ruojun Wang.
5. Microbiota in Rosacea. Hei Sung Kim.
6. Skin Microbiota and Clinical Associations in Netherton Syndrome. Veera Sillanpa, Tatiany Aparecida Teixeira Soratto, Elna Era, , Mauricio Barrientos-Somarribas, Katariina Hannula-Jouppi, Andersson and AnnamariRanki.
7. The Human Microbiota and Skin Cancer Yu Ri Woo , Sang Hyun Cho , JeongDeuk Lee and Hei Sung Kim.
8. Disordered cutaneous microbiota in systemic lupus erythematosus. Cancan Huang, Xiaoqing Yia, Hai Longa, GuiyingZhanga, HaijingWua, Ming Zhaoa, Qianjin Lua.
9. The role of the microbiome in scalp hair follicle biology and disease Katarzyna Polak-Witka Lidia Rudnicka, Ulrike Blume-Peytavi, Annika Vogt.
10. The “Maskne” microbiome – pathophysiology and therapeutics Wan-Lin Teo, MBBS, MRCS (UK), FAMS (Dermatology).
11. Disordered cutaneous microbiota in systemic lupus erythematosus T Cancan Huang,a,b,1, Xiaoqing Yia,b,1, Hai Longa,b, GuiyingZhanga,b, HaijingWua,b, Ming Zhaoa,b,**, Qianjin Lua.

12. A distinct cutaneous microbiota profile in autoimmune bullous disease patients MorMiodovnik, Axel Künstner, Ewan A. Langan, Detlef Zillikens, Regine Gläser, Eli Sprecher, John F. Baines, Enno Schmidt, Saleh M. Ibrahim.
13. Cutaneous Leishmaniasis Induces a Transmissible Dysbiotic Skin Microbiota that Promotes Skin Inflammation Ciara Gimblet, Jacquelyn S. Meisel, Michael A. Loesche, ..., Edgar M. Carvalho, Phillip Scott, Elizabeth A. Grice.
14. Microbiome and Human Aging: Probiotic and Prebiotic Potentials in Longevity, Skin Health and Cellular Senescence Jacqueline Lena Boyajian, Merry Ghebretatios, Sabrina Schaly, Paromita Islam and Satya Prakash.
15. Topical Probiotics: More Than a Skin Deep Mohammed Habeebuddin 1, Ranjith Kumar Karnati², Predeepkumar Narayanappa Shiroorkar, Sreeharsha Nagaraja and Santosh Fattepur, Syed Mohammed Basheeruddin Asdaq Md. Khalid Anwer.
16. Non-Melanoma Skin Cancer: news from microbiota research. Diletta Francesca Squarzanti, Elisa Zavattaro, Stefania Pizzimenti, Angela Amoroso, Paola Savoia & Barbara Azzimonti.
17. The Skin Microbiome: A New Actor in Inflammatory Acne. Brigitte Dréno, Marie Ange Dagnelie, Amir Khammari, Stéphane Corvec.
18. Analysis of Matched Skin and Gut Microbiome of Patients with Vitiligo Reveals Deep Skin Dysbiosis: Link with Mitochondrial and Immune Changes. Hanene Bziouche, Kotryna Simonytė-Sjodin, Christina E. West, Abdallah Khemis, Stéphane Rocchi, Thierry Passeron, Meri K. Tulic.
19. Differences in the skin microbial community between patients with active and stable vitiligo based on 16S rRNA gene sequencing. Haojie Lu, Jinhui Xu, Yebei Hu, Haixin Luo, Yi Chen, Bo Xie, Xiuzu Song.
20. Ng CY, Huang YH, Chu CF, Wu TC, Liu SH. Risks for Staphylococcus aureus colonization in patients with psoriasis: a systematic review and meta-analysis. *Br J Dermatol.* 2017 Oct;177(4):967-977. doi: 10.1111/bjd.15366. Epub 2017 Sep 8. PMID: 28160277.
21. Myles IA, Castillo CR, Barbian KD, Kanakabandi K, Virtaneva K, Fitzmeyer E, Paneru M, Otaizo-Carrasquero F, Myers TG, Markowitz TE, Moore IN, Liu X, Ferrer M, Sakamachi Y, Garantziotis S, Swamydas M, Lionakis MS, Anderson ED, Earland NJ, Ganesan S, Sun AA, Bergerson JRE, Silverman RA, Petersen M, Martens CA, Datta SK. Therapeutic responses to *Roseomonas mucosa* in atopic dermatitis may involve lipid-mediated TNF-related epithelial repair. *Sci Transl Med.* 2020 Sep 9;12(560):eaaz8631. doi: 10.1126/scitranslmed.aaz8631. PMID: 32908007; PMCID: PMC8571514.
22. Berg, G., Rybakova, D., Fischer, D. et al. Microbiome definition re-visited: old concepts and new challenges. *Microbiome* 8, 103 (2020). <https://doi.org/10.1186/s40168-020-00875-0>
23. Dhariwala MO, Scharschmidt TC. Baby's skin bacteria: first impressions are long-lasting. *Trends Immunol.* 2021 Dec;42(12):1088-1099. doi: 10.1016/j.it.2021.10.005. Epub 2021 Nov 4. PMID: 34743922; PMCID: PMC9206859.
24. Sanford JA, Gallo RL. Functions of the skin microbiota in health and disease. *Semin Immunol* 2013;30:370–7.
25. Emter R, Natsch A. The sequential action of a dipeptidase and a \square -lyase is required for the release of the human body odorant 3-methyl-3-sulfanylhexan-1-ol from a secreted Cys-Gly(S) conjugate by *Corynebacteria*. *J Biol Chem* 2008;283:20645–52.
26. Findley K, Oh J, Yang J, Conlan S, Deming C, Meyer JA, et al. Topographic diversity of fungal and bacterial communities in human skin. *Nature* 2013;498:367–70.
27. Staudinger T, Pipal A, Redl B. Molecular analysis of the prevalent microbiota of human male and female forehead skin compared to forearm skin and the influence of make-up. *J Appl Microbiol* 2011;110:1381–9.
28. Fierer N, Hamady M, Lauber CL, Knight R. The influence of sex, handedness, and washing on the diversity of hand surface bacteria. *Proc Natl Acad Sci U S A* 2008;105:17994–9.
29. Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. *Nat Rev Immunol* 2012;12:503–16.
30. Elias PM. The skin barrier as an innate immune element. *Semin Immunopathol* 2007;29:3–14.
31. Iwase T, Uehara Y, Shinji H, Tajima A, Seo H, Takada K, et al. *Staphylococcus epidermidis* Esp inhibits *Staphylococcus aureus* biofilm formation and nasal colonization. *Nature* 2010;465:346–9.
32. Wang Y, Kuo S, Shu M, Yu J, Huang S, Dai A, et al. *Staphylococcus epidermidis* in the human skin microbiome mediates fermentation to inhibit the growth of *Propionibacterium acnes*: implications of probiotics in acne vulgaris. *Appl Microbiol Biotechnol* 2014;98: 411–24.
33. Wang Y, Kao MS, Yu J, Huang S, Marito S, Gallo RL, et al. A precision microbiome approach using sucrose for selective augmentation of *Staphylococcus epidermidis* fermentation against *Propionibacterium acnes*. *Int J Mol Sci* 2016;17:E1870.